TP53 alterations are also suggested to alter ovarian cancer survival in BRCA1 germ line patients [13,14], while other groups concludes with a failure of BRCA1 dysfunction to alter ovarian cancer survival [16]. Here, TP53 is linked to ovarian carcinoma.